BIOQuébec Mr. Lebrun discusses the role that BIOQuébec plays in the industry, its aims in representing several sectors and their plans for the coming years. Could you introduce BIOQuébec and its main priorities to our readers? BIOQuébec is a voluntary trade association representing Québec-based life sciences organizations. Its membership includes biotechnology…
Botanical drugs The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and US markets. Mr. Hsu, can you please introduce our readers to yourself and to TCM Biotech? Shining Hsu (SH): I…
UAE Marwan Abdulaziz, Executive Director of Dubiotech, talks about the growing Life Sciences industry in the UAE, why it is important for the government to encourage biotech studies in universities, and what the major industry challenges will look like over the next several years. Dubiotech is the first free zone…
UAE Ashraf Allam, Regional Managing Director of Amgen, talks about the main challenges the company has faced, the benefit of building a company in the UAE, and the growth strategy of Amgen—past, present and future. Amgen is a relative newcomer to the region having only established is operations in 2006.…
Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…
Biotechnology Ashraf Allam, Regional Managing Director of Amgen, talks about the main challenges the company has faced, the benefit of building a company in the UAE, and the growth strategy of Amgen—past, present and future. Amgen is a relatively newcomer to the region having only established is operations in 2006. As…
Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…
CROs Riaz Bandali, President ESD of InVentiv Health Clinical discusses the ways in which the company’s unique combination of different technologies and capabilities will help lead the way to better healthcare and the ability to treat individuals more effectively. What was your initial mandate at InVentiv? Like many Canadian health and…
R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…
See our Cookie Privacy Policy Here
